NCT07407348

A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

Bioequivalence of Two Survodutide (BI 456906) Formulations Via Subcutaneous Administration After Multiple Doses (an Open-label, Randomised, Multiple-dose, Crossover Trial)

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this trial is to assess bioequivalence of two formulations of survodutide (formulation A and formulation B6) after multiple-dose treatment in male and female trial participants living with overweight or obesity.

Conditions

• Healthy
• Obesity
• Overweight

Interventions

Type	Name	Description
COMBINATION_PRODUCT	Formulation A	Formulation A of survodutide
COMBINATION_PRODUCT	Formulation B6	Formulation B6 of survodutide

Timeline

• Start date: 2026-02-26
• Primary completion: 2027-01-26
• Completion: 2027-03-02
• First posted: 2026-02-12
• Last updated: 2026-03-17

Locations

1 site across 1 country: United Kingdom